Lead Candidate

all catalysts(0)

nothing on the calendar yet

News(10)

• After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on
  Aardvark Therapeutics has confirmed it is walking away from recently terminated phase 3 trials, telling investors it has no plans to resume the studies “as previously designed” as it works to find…
  fiercebiotech · 6h ago
• Aura, Schrödinger trim workforces
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• Epicrispr, Infinimmune snag combined $165M in VC cash
  Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
  biospace · 1d ago
• Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
  Aura Biosciences is refocusing under its recently installed CEO, laying off 20% of its employees and overhauling its C-suite as it narrows its focus on ocular oncology.
  fiercebiotech · 1d ago
• Regeneron backs $75M series A for antibody upstart Infinimmune
  Infinimmune has amassed further fuel to power its antibody discovery engine, netting a $75 million series A headlined by Regeneron’s venture arm.
  fiercebiotech · 1d ago
• Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
  Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.
  biospace · 2d ago
• ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
  The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of tumors due to qualms over the drug’s manufacturing.
  fiercebiotech · 2d ago
• Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
  Jazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.
  fiercebiotech · 2d ago
• BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
  Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.
  fiercebiotech · 5d ago
• Braveheart pumps more life into biotech IPO market with $382M expected debut
  Braveheart Bio has emerged on the Nasdaq with an upsized expected initial public offering—marking the public entrance of the twenty-second biotech this year.
  biospace · 6d ago